Atom Investors LP Raises Stock Holdings in Cencora, Inc. $COR

Atom Investors LP increased its position in Cencora, Inc. (NYSE:COR) by 41.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,942 shares of the company’s stock after purchasing an additional 6,448 shares during the period. Atom Investors LP’s holdings in Cencora were worth $7,411,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. United Bank grew its stake in shares of Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after acquiring an additional 305 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in shares of Cencora in the second quarter worth $595,000. Treasurer of the State of North Carolina grew its stake in shares of Cencora by 7.9% in the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after acquiring an additional 6,244 shares during the last quarter. Diversify Advisory Services LLC grew its stake in shares of Cencora by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after acquiring an additional 1,253 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Cencora by 26.0% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after acquiring an additional 15,154 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Down 0.1%

Cencora stock opened at $281.22 on Wednesday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The stock has a market capitalization of $54.71 billion, a PE ratio of 21.57, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The business’s fifty day moving average is $287.49 and its 200 day moving average is $326.05.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period last year, the business earned $4.42 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has authorized a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio is currently 18.40%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. UBS Group increased their target price on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley set a $342.00 target price on Cencora in a research note on Friday, May 8th. Weiss Ratings cut Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Robert W. Baird cut their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.